Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Urinary Bladder Neoplasms 3Neoplasms 2Urothelial Bladder Cancer 1Urologic Neoplasms 1Urinary Bladder Diseases 1Recurrence 1Driving Under the Influence 1Disease Progression 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 21pomalidomide 18Lenalidomide 18Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Cisplatin 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8Carboplatin 8obinutuzumab 7cemiplimab 7Drug Therapy 7Bevacizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Multiparametric Magnetic Resonance Imaging × 1 year × Clear all
NCT06126172 2026-03-20

Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions

Chang Gung Memorial Hospital

Phase NA Active not recruiting
125 enrolled
Genitourinary

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡